Alendronate therapy in men with primary hyperparathyroidism.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Volumn 15, Issue 7, 2009, Pages 705-713

  Khan, Aliya A ^a   Bilezikian, John P ^a   Kung, Annie ^a   Dubois, Sacha J ^a   Standish, Timothy I ^a   Syed, Zeba A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; POSTMENOPAUSE; PREMENOPAUSE; SEX FACTORS; TREATMENT OUTCOME;

EID: 77449100380     PISSN: None     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP08178.ORR     Document Type: Article

References (0)